Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Pasireotide> ?p ?o. }
Showing items 1 to 60 of
60
with 100 items per page.
- Pasireotide abstract "Pasireotide (SOM230, trade name Signifor) is an orphan drug approved in the U.S. and Europe for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog which has a 40-fold increased affinity to somatostatin receptor 5 than other somatostatin analogs.The drug showed therapeutical potential in a recent study (PASPORT-CUSHINGS B2305) where 162 patients were treated with either 2x 600 µg or 2x 900 µg pasireotide s.c. daily. The effectiveness of the treatment was checked by the UFC-value (urinary free cortisol) after six months of treatment. The mean reduction of UFC after six months was 47.9%, which also lead to amelioration of clinical symptoms such as blood pressure, cholesterol value, and weight loss.Pasireotide was approved by the EMEA in October 2009 and by the FDA in December 2012.".
- Pasireotide atcPrefix "H01".
- Pasireotide atcSuffix "CB05".
- Pasireotide casNumber "396091-73-9".
- Pasireotide chEBI "72312".
- Pasireotide fdaUniiCode "98H1T17066".
- Pasireotide iupacName "[(3S,6S,9S,12R,15S,18S,20R)-9-(4-aminobutyl)-3-benzyl-12-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-6-[(4-phenylmethoxyphenyl)methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-(2-aminoethyl)carbamate".
- Pasireotide pubchem "9941444".
- Pasireotide thumbnail Pasireotide.svg?width=300.
- Pasireotide wikiPageID "31715666".
- Pasireotide wikiPageRevisionID "592547155".
- Pasireotide atcPrefix "H01".
- Pasireotide atcSuffix "CB05".
- Pasireotide c "58".
- Pasireotide casNumber "396091".
- Pasireotide chebi "72312".
- Pasireotide h "66".
- Pasireotide hasPhotoCollection Pasireotide.
- Pasireotide iupacName "[-9--3-benzyl-12--2,5,8,11,14,17-hexaoxo-15-phenyl-6-[methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-carbamate".
- Pasireotide kegg "D10147".
- Pasireotide legalStatus "Rx-only".
- Pasireotide licenceEu "Signifor".
- Pasireotide molecularWeight "1107.26".
- Pasireotide n "10".
- Pasireotide o "9".
- Pasireotide pubchem "9941444".
- Pasireotide routesOfAdministration "Subcutaneous".
- Pasireotide synonyms "SOM230".
- Pasireotide tradename "Signifor".
- Pasireotide unii "98".
- Pasireotide verifiedfields "changed".
- Pasireotide verifiedrevid "451604097".
- Pasireotide watchedfields "changed".
- Pasireotide subject Category:Hormonal_agents.
- Pasireotide subject Category:Orphan_drugs.
- Pasireotide type Agent109190918.
- Pasireotide type Agent114778436.
- Pasireotide type CausalAgent100007347.
- Pasireotide type Drug103247620.
- Pasireotide type HormonalAgents.
- Pasireotide type Matter100020827.
- Pasireotide type OrphanDrugs.
- Pasireotide type PhysicalEntity100001930.
- Pasireotide type Substance100020090.
- Pasireotide type Drug.
- Pasireotide type FunctionalSubstance.
- Pasireotide comment "Pasireotide (SOM230, trade name Signifor) is an orphan drug approved in the U.S. and Europe for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis.".
- Pasireotide label "Pasireotide".
- Pasireotide label "Pasireotide".
- Pasireotide label "Pasireotide".
- Pasireotide sameAs Pasiréotide.
- Pasireotide sameAs Pasireotide.
- Pasireotide sameAs Pasireotide.
- Pasireotide sameAs m.0gmcrbc.
- Pasireotide sameAs Q3896970.
- Pasireotide sameAs Q3896970.
- Pasireotide sameAs Pasireotide.
- Pasireotide wasDerivedFrom Pasireotide?oldid=592547155.
- Pasireotide depiction Pasireotide.svg.
- Pasireotide isPrimaryTopicOf Pasireotide.